Drugs / SC-Ad6-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04839042 | Jun 2021 → Mar 2025 | COVID-19 | Moat Biotechnology Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC-Ad6-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04839042 ↗ |
| Modality | Vaccine | “COVID-19 Vaccine” NCT04839042 ↗ |
| Route | Inhaled | “administered via the intramuscular (IM), intranasal (IN) or inhaled (IH) route” NCT04839042 ↗ |
| Route | Intramuscular | “administered via the intramuscular (IM), intranasal (IN) or inhaled (IH) route” NCT04839042 ↗ |
| Route | Intranasal | “administered via the intramuscular (IM), intranasal (IN) or inhaled (IH) route” NCT04839042 ↗ |